{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:15:09Z","timestamp":1783149309388,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wuxi Traditional Chinese Medicine Hospital Innovation Development Fund Project","award":["ZYYZD24001"],"award-info":[{"award-number":["ZYYZD24001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75421-1","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:08:40Z","timestamp":1735873720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Data mining and analysis of adverse events of Vedolizumab based on the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Qinyun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"1","key":"75421_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","volume":"5","author":"V Jairath","year":"2020","unstructured":"Jairath, V. & Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 5(1), 2\u20133 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"75421_CR2","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai, Z., Wang, S. & Li, J. Treatment of inflammatory bowel disease: a comprehensive review. Front. Med. 8, 765474 (2021).","journal-title":"Front. Med."},{"key":"75421_CR3","doi-asserted-by":"publisher","first-page":"612830","DOI":"10.3389\/fcell.2021.612830","volume":"9","author":"M Luzentales-Simpson","year":"2021","unstructured":"Luzentales-Simpson, M. et al. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front. Cell. Dev. Biol. 9, 612830 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"75421_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu, H. et al. Mining and analysis of adverse event signals of cariprazine based on the real-world data of FAERS database. J. Affect. Disord. 347, 45\u201350 (2024).","journal-title":"J. Affect. Disord."},{"key":"75421_CR5","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J. Psychiatry. 90, 103828 (2023).","journal-title":"Asian J. Psychiatry"},{"key":"75421_CR6","doi-asserted-by":"crossref","unstructured":"Jiang, Y. et al. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur. Arch. Psychiatry Clin. NeuroSci. 1\u20139. (2023).","DOI":"10.1007\/s00406-023-01732-5"},{"key":"75421_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229 (2024).","journal-title":"J. Affect. Disord."},{"key":"75421_CR8","doi-asserted-by":"crossref","unstructured":"Ou, M. et al. Analysis of the adverse events of Aristada: a real-world study based on FAERS database. Asian J. Psychiatry. 94, 103968 (2024).","DOI":"10.1016\/j.ajp.2024.103968"},{"issue":"8","key":"75421_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown, E. G. Using MedDRA: implications for risk management. Drug Saf. 27(8), 591\u2013602 (2004).","journal-title":"Drug Saf."},{"issue":"8","key":"75421_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13(8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"75421_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans, S. J. W., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"75421_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"75421_CR13","doi-asserted-by":"crossref","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system.  Am. Stat. 53(3), 177\u2013190 (1999).","DOI":"10.1080\/00031305.1999.10474456"},{"issue":"12","key":"75421_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41575-020-0354-0","volume":"17","author":"WA Goodman","year":"2020","unstructured":"Goodman, W. A., Erkkila, I. P. & Pizarro, T. T. Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nat. Revi Gastroenterol. Hepatol. 17(12), 740\u2013754 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75421_CR15","doi-asserted-by":"crossref","unstructured":"Loftus, E. V. Jr et al. Long-term safety of Vedolizumab for inflammatory bowel disease. Aliment. Pharmacol. Therap. 52(8), 1353\u20131365 (2020).","DOI":"10.1111\/apt.16060"},{"issue":"3","key":"75421_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn, W. J. et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 158(3), 562\u2013572.e12 (2020).","journal-title":"Gastroenterology"},{"issue":"1","key":"75421_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-022-02347-1","volume":"22","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet, L. et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 22(1), 1\u201316 (2022).","journal-title":"BMC Gastroenterol."},{"issue":"10","key":"75421_CR18","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/ibd\/izz222","volume":"26","author":"MT Osterman","year":"2020","unstructured":"Osterman, M. T. et al. Mucosal biomarker of innate immune activation predicts response to vedolizumab in Crohn\u2019s disease. Inflamm. Bowel Dis. 26(10), 1554\u20131561 (2020).","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"75421_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/ecco-jcc\/jjab067","volume":"15","author":"B Ungar","year":"2021","unstructured":"Ungar, B. et al. Dose optimisation for loss of response to Vedolizumab\u2014pharmacokinetics and immune mechanisms. J. Crohn\u2019s Colitis. 15(10), 1707\u20131719 (2021).","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"3","key":"75421_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1751-2980.12849","volume":"21","author":"XY Guo","year":"2020","unstructured":"Guo, X. Y., Liu, X. J. & Hao, J. Y. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J. Dig. Dis. 21(3), 147\u2013159 (2020).","journal-title":"J. Dig. Dis."},{"key":"75421_CR21","doi-asserted-by":"crossref","unstructured":"Hsu, P. et al. Responsiveness to Vedolizumab therapy in ulcerative colitis is associated with alterations in immune cell-cell communications. Inflamm. Bowel Dis. 29(10), 1602-1612 (2023).","DOI":"10.1093\/ibd\/izad084"},{"issue":"7","key":"75421_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/bcp.14235","volume":"86","author":"L Bertani","year":"2020","unstructured":"Bertani, L. et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br. J. Clin. Pharmacol. 86(7), 1296\u20131305 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"75421_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpdd.891","volume":"10","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. Assessment of vedolizumab disease-drug\u2010drug interaction potential in patients with inflammatory bowel diseases. Clin. Pharmacol. Drug Dev. 10(7), 734\u2013747 (2021).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"75421_CR24","doi-asserted-by":"crossref","unstructured":"Stanke-Labesque, F. et al. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol. Therap. 215, 107627 ( 2020).","DOI":"10.1016\/j.pharmthera.2020.107627"},{"key":"75421_CR25","doi-asserted-by":"publisher","first-page":"175628482110327","DOI":"10.1177\/17562848211032790","volume":"14","author":"K Mitrova","year":"2021","unstructured":"Mitrova, K. et al. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Therap. Adv. Gastroenterol. 14, 17562848211032790 (2021).","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"1S","key":"75421_CR26","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1097\/MEG.0000000000002166","volume":"33","author":"T Innocenti","year":"2021","unstructured":"Innocenti, T. et al. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 33(1S), e574\u2013e579 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75421-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T02:02:53Z","timestamp":1735956173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["75421"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75421-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"278"}}